Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes

Autor: Stanislas Pol, Christian Boitard, Nathalie Gault, Jimmy Mullaert, Pauline Manchon, J.M. Castille, Sébastien Czernichow, Thierry Poynard, Jean-François Gautier, Béatrice Parfait, Benoit Terris, Estelle Marcault, Anaïs Vallet-Pichard, Etienne Larger, Valérie Paradis, Cédric Laouénan, F. Drane, Laurent Castera, Valentina Peta, Dominique Valla, Angelique Brzustowski, Olivier Deckmyn, Pierre Bedossa, Nassima Si Mohammed, Mark Ibberson, Dominique Roulot
Přispěvatelé: Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), BioPredictive [Paris], Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique (CIC 1425), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Chercheur indépendant, Hôpital Cochin [AP-HP], Swiss Institute of Bioinformatics [Lausanne] (SIB), Université de Lausanne (UNIL), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Université de Lausanne = University of Lausanne (UNIL), Gestionnaire, HAL Sorbonne Université 5
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Liver Cirrhosis
medicine.medical_specialty
Biopsy
Type 2 diabetes
Gastroenterology
03 medical and health sciences
Liver disease
0302 clinical medicine
Fibrosis
Non-alcoholic Fatty Liver Disease
Internal medicine
Post-hoc analysis
Non‐invasive Testing for Nash with Type 2 Diabetes
medicine
Humans
Superfast
Pharmacology (medical)
Prospective Studies
030304 developmental biology
0303 health sciences
Hepatology
business.industry
FibroTest
Type 2 Diabetes Mellitus
Reproducibility of Results
[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
medicine.disease
[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology
3. Good health
Diabetes Mellitus
Type 2
Liver
030211 gastroenterology & hepatology
Steatohepatitis
Steatosis
business
Zdroj: Alimentary Pharmacology & Therapeutics (Suppl)
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 54 (7), pp.952-966. ⟨10.1111/apt.16543⟩
Alimentary Pharmacology & Therapeutics
ISSN: 0953-0673
1365-2036
DOI: 10.1111/apt.16543⟩
Popis: Summary Background One of the unmet needs in patients with type 2 diabetes mellitus (T2DM) is the prediction of non‐alcoholic liver disease by non‐invasive blood tests, for each of the three main histological features, fibrosis, non‐alcoholic steatohepatitis (NASH) and steatosis. Aims To validate externally the performances of a recent panel, Nash‐FibroTest, for the assessment of the severity of fibrosis stages, NASH grades and steatosis grades. Methods We prospectively analysed 272 patients with T2DM. Standard definitions of stages and grades were used, and analyses were centralised and blinded. The performances of the FibroTest, NashTest‐2 and SteatoTest‐2 were assessed using the Obuchowski measure (OM), the main outcome recommended as a summary measure of accuracy includeing all pairwise stages and grades comparisons, which is not provided par the extensively used binary area under the ROC curve. Results The diagnostic performance of each component of the panel was significant. OM (SE; significance) of the FibroTest, the NashTest‐2 and the SteatoTest‐2 was 0.862 (0.012; P
From a single blood sample, the Nash FibroTest panel provides non‐invasive diagnosis of the stages of fibrosis and the grades of NASH, including ballooning and lobular inflammation, and steatosis grades in patients with type 2 diabetes mellitus.
Databáze: OpenAIRE
Externí odkaz: